- Home
- MDAI vs COEP Comparison
MDAI vs COEP Comparison
Compare MDAI & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDAI
- COEP
- Stock Information
- Founded
- MDAI 2013
- COEP 2017
- Country
- MDAI United States
- COEP United States
- Employees
- MDAI N/A
- COEP N/A
- Industry
- MDAI Medical/Dental Instruments
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MDAI Health Care
- COEP Health Care
- Exchange
- MDAI Nasdaq
- COEP Nasdaq
- Market Cap
- MDAI 27.8M
- COEP 30.5M
- IPO Year
- MDAI N/A
- COEP N/A
- Fundamental
- Price
- MDAI $1.25
- COEP $11.50
- Analyst Decision
- MDAI Strong Buy
- COEP
- Analyst Count
- MDAI 2
- COEP 0
- Target Price
- MDAI $4.75
- COEP N/A
- AVG Volume (30 Days)
- MDAI 341.2K
- COEP 25.5K
- Earning Date
- MDAI 05-06-2025
- COEP 05-09-2025
- Dividend Yield
- MDAI N/A
- COEP N/A
- EPS Growth
- MDAI N/A
- COEP N/A
- EPS
- MDAI N/A
- COEP N/A
- Revenue
- MDAI $29,581,000.00
- COEP N/A
- Revenue This Year
- MDAI N/A
- COEP N/A
- Revenue Next Year
- MDAI $102.58
- COEP N/A
- P/E Ratio
- MDAI N/A
- COEP N/A
- Revenue Growth
- MDAI 63.83
- COEP N/A
- 52 Week Low
- MDAI $0.82
- COEP $2.31
- 52 Week High
- MDAI $3.25
- COEP $13.70
- Technical
- Relative Strength Index (RSI)
- MDAI 44.43
- COEP 68.30
- Support Level
- MDAI $1.17
- COEP $9.16
- Resistance Level
- MDAI $1.28
- COEP $11.69
- Average True Range (ATR)
- MDAI 0.09
- COEP 0.52
- MACD
- MDAI 0.02
- COEP 0.29
- Stochastic Oscillator
- MDAI 44.95
- COEP 92.82
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.